{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T11:40:02Z","timestamp":1716291602893},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,12,11]],"date-time":"2013-12-11T00:00:00Z","timestamp":1386720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mantle cell lymphoma (MCL) is a rare non\u2010Hodgkin's lymphoma entity with a heterogeneous clinical presentation. Various therapeutic considerations in MCL for younger and elderly patients were used over the past decade. We retrospectively analyzed all 44 patients consecutively treated in a tertiary hospital between 2000 and 2010 with newly diagnosed MCL. Patient characteristics, treatment regimens and biological markers were evaluated with regard to overall survival (OS). Treatment regimens were categorized into internationally accepted intensive standard therapies and less intensive alternative treatment regimens given with palliative intent. Biological markers were correlated with clinical outcome by univariate analysis. The median age of the entire study group was 66\u2009years (range: 42\u201388), with 23 (52%) patients \u226565\u2009years. Thirty\u2010one (70%) patients received standard regimens, the remaining 13 (30%) patients were treated with other, less intensive regimens with palliative intent. With a median follow\u2010up of 5.25\u2009years, the three\u2010year OS rate was 60% [95% confidence interval (CI) 0.47\u20130.77]. Patients treated with standard regimens had a three\u2010year survival rate of 77% (range: 64\u201394%). Of these, patients younger than 65\u2009years were observed to have better OS (83% at 3\u2009years; 95% CI 68\u2013100%) than those older than 65\u2009years (69% at 3\u2009years; 95% CI 48\u201399%). In univariate analysis, the only parameters with a statistically significant prognostic impact on OS were absolute monocyte count as a continuous variable, lactate dehydrogenase and absolute lymphocyte count (&gt;0.5\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/l) at diagnosis. In conclusion, our data of an unselected group of patients with newly diagnosed MCL treated at a single centre tertiary hospital are in line with results from larger randomized trials demonstrating an improved OS rate of younger as well as elderly MCL patients within the last decade. Copyright \u00a9 2013 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.2123","type":"journal-article","created":{"date-parts":[[2013,12,12]],"date-time":"2013-12-12T03:30:45Z","timestamp":1386819045000},"page":"192-196","source":"Crossref","is-referenced-by-count":1,"title":["Outcome of mantle cell lymphoma patients treated at a single institution over the past decade"],"prefix":"10.1002","volume":"32","author":[{"given":"Felicitas","family":"Hitz","sequence":"first","affiliation":[{"name":"Oncology\u2010Haematology Cantonal Hospital of St Gallen St Gallen Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Diem","sequence":"additional","affiliation":[{"name":"Oncology\u2010Haematology Cantonal Hospital of St Gallen St Gallen Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah R.","family":"Haile","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit Cantonal Hospital of St Gallen St Gallen Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Ess","sequence":"additional","affiliation":[{"name":"Cancer Registry of St.Gallen and Appenzell St.Gallen Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Cerny","sequence":"additional","affiliation":[{"name":"Oncology\u2010Haematology Cantonal Hospital of St Gallen St Gallen Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Mey","sequence":"additional","affiliation":[{"name":"Medical Oncology and Haematology Cantonal Hospital of Graub\u00fcnden Chur Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,12,11]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk152"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3883"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200920"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-179739"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-370320"},{"key":"e_1_2_6_7_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.151.151","article-title":"Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA\u2010C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL younger trial of the European mantle cell lymphoma network (MCL net)","volume":"120","author":"Hermine O","year":"2012","journal-title":"Blood"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08228.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-236570"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12409"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12531"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_6_14_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox D","year":"1972","journal-title":"J R Stat Soc Ser B (Methodological)"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(95)00048-8"},{"key":"e_1_2_6_16_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R CORE TEAM","year":"2013"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.587560"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07498.x"},{"issue":"3","key":"e_1_2_6_20_1","first-page":"425","article-title":"Rituximab and DHAP followed by intensive therapy with autologous stem\u2010cell transplantation as first\u2010line therapy for mantle cell lymphoma","volume":"91","author":"De Guibert S","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2123","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T11:15:23Z","timestamp":1716290123000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,11]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1002\/hon.2123"],"URL":"https:\/\/doi.org\/10.1002\/hon.2123","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,11]]}}}